Global Therapeutic Ultrasound Company Submits Application for HIFU System
By MedImaging International staff writers Posted on 27 Apr 2016 |
Image: The robot-assisted Focal One HIFU device (Photo courtesy of EDAP TMS).
A global leader in therapeutic ultrasound systems has announced the submission of a 510(k) application for the clearance of its next generation non-invasive HIFU device to the US Food and Drug Administration (FDA).
The company received US FDA clearance in 2015 for another robotic High-Intensity Focused Ultrasound (HIFU) prostate tissue ablation system. HIFU treatment is minimally invasive, and is an effective treatment option for prostatic tissue ablation. The treatment has minimal side effects, and is normally recommended for treatment of localized stage T1 and T2 prostate cancer.
The new robot-assisted Focal One HIFU device, the EDAP TMS (Paris, France) Focal One system, is intended for focal therapy of prostate cancer. The system already has the CE Mark (Conformité Européenne) for the European market.
The non-invasive Focal One robot-assisted prostate tumorectomy device combines imaging and treatment technologies. The device provides focal therapy, Magnetic Resonance (MR)-fused imaging, precise and efficient therapeutic HIFU energy, and validation imaging using contrast-enhanced ultrasound when treatment is complete.
Marc Oczachowski, CEO of EDAP, said, “We are pleased to submit our Focal One HIFU device file to the FDA to further our goal of making EDAP's full range of HIFU products available to both urologists and patients in the U.S. There is a clear, growing demand from the worldwide urology community for non-invasive options for the ablation of prostatic tissue, and we are well positioned to address this market with our complementary Ablatherm and Focal One devices. We believe that HIFU has the potential to become a standard of care tool for prostate ablation. We are extremely excited by the progress of the U.S. commercial launch of Ablatherm Robotic HIFU and look forward to working with the FDA on the clearance process for Focal One."
Related Links:
EDAP TMS
The company received US FDA clearance in 2015 for another robotic High-Intensity Focused Ultrasound (HIFU) prostate tissue ablation system. HIFU treatment is minimally invasive, and is an effective treatment option for prostatic tissue ablation. The treatment has minimal side effects, and is normally recommended for treatment of localized stage T1 and T2 prostate cancer.
The new robot-assisted Focal One HIFU device, the EDAP TMS (Paris, France) Focal One system, is intended for focal therapy of prostate cancer. The system already has the CE Mark (Conformité Européenne) for the European market.
The non-invasive Focal One robot-assisted prostate tumorectomy device combines imaging and treatment technologies. The device provides focal therapy, Magnetic Resonance (MR)-fused imaging, precise and efficient therapeutic HIFU energy, and validation imaging using contrast-enhanced ultrasound when treatment is complete.
Marc Oczachowski, CEO of EDAP, said, “We are pleased to submit our Focal One HIFU device file to the FDA to further our goal of making EDAP's full range of HIFU products available to both urologists and patients in the U.S. There is a clear, growing demand from the worldwide urology community for non-invasive options for the ablation of prostatic tissue, and we are well positioned to address this market with our complementary Ablatherm and Focal One devices. We believe that HIFU has the potential to become a standard of care tool for prostate ablation. We are extremely excited by the progress of the U.S. commercial launch of Ablatherm Robotic HIFU and look forward to working with the FDA on the clearance process for Focal One."
Related Links:
EDAP TMS
Latest Ultrasound News
- Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease
- Super-Resolution Imaging Technique Could Improve Evaluation of Cardiac Conditions
- First AI-Powered POC Ultrasound Diagnostic Solution Helps Prioritize Cases Based On Severity
- Largest Model Trained On Echocardiography Images Assesses Heart Structure and Function
- Groundbreaking Technology Enables Precise, Automatic Measurement of Peripheral Blood Vessels
- Deep Learning Advances Super-Resolution Ultrasound Imaging
- Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection
- AI-Guided Ultrasound System Enables Rapid Assessments of DVT
- Focused Ultrasound Technique Gets Quality Assurance Protocol
- AI-Guided Handheld Ultrasound System Helps Capture Diagnostic-Quality Cardiac Images
- Non-Invasive Ultrasound Imaging Device Diagnoses Risk of Chronic Kidney Disease
- Wearable Ultrasound Platform Paves Way for 24/7 Blood Pressure Monitoring On the Wrist
- Diagnostic Ultrasound Enhancing Agent to Improve Image Quality in Pediatric Heart Patients
- AI Detects COVID-19 in Lung Ultrasound Images
- New Ultrasound Technology to Revolutionize Respiratory Disease Diagnoses
- Dynamic Contrast-Enhanced Ultrasound Highly Useful For Interventions